olmesartan medoxomil + losartan potassium

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Essential Hypertension

Conditions

Essential Hypertension

Trial Timeline

May 1, 2002 → Sep 1, 2003

NCT ID

NCT00857285

About olmesartan medoxomil + losartan potassium

olmesartan medoxomil + losartan potassium is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00857285. Target conditions include Essential Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00856271	Phase 3	Completed	Aug 1, 2004	Apr 1, 2005	Essential Hypertension
NCT00857285	Phase 3	Completed	May 1, 2002	Sep 1, 2003	Essential Hypertension

Competing Products

20 competing products in Essential Hypertension

See all competitors

Product	Company	Stage	Hype Score
L04RD1 + L04TD3	Celltrion	Phase 1	33
Azilsartan Medoxomil	Celltrion	Pre-clinical	23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mg	Celltrion	Phase 3	77
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg	Yuhan	Approved	85
Anagre Cap.	Yuhan	Approved	85
Telmisartan/Amlodipine/Chlorthalidone(Truset)	Yuhan	Pre-clinical	23
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo + olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil/hydrochlorothiazide tablets + olmesartan medoxomil/hydrochlorothiazide tablets	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil + hydrochlorothiazide, if necessary + losartan + hydrochlorothiazide, if necessary	Daiichi Sankyo	Phase 3	77
CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo	Daiichi Sankyo	Phase 3	77
CS-3150 + olmesartan medoxomil	Daiichi Sankyo	Pre-clinical	23
olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo + Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine	Daiichi Sankyo	Phase 3	77
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenolol	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary	Daiichi Sankyo	Approved	85
CS-3150 + Eplerenone	Daiichi Sankyo	Phase 3	77
Olmesartan medoxomil 40 mg - Amlodipine 10 mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary	Daiichi Sankyo	Approved	85
Olmesartan medoxomil + Losartan + Furosemide oral tablets	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil + amlodipine	Daiichi Sankyo	Phase 3	77
olmesartan medoxomil + amlodipine + hydrochlorothiazide	Daiichi Sankyo	Phase 3	77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved